Joshua J. Neumiller, PharmD, CDCES, of the American Diabetes Association discusses pharmacists’ role in diabetes and CKD care from ASN Kidney Week 2026
|Videos|June 23, 2015
Tips for Inclusion in an ACO or PCMH Model
Sandra Leal, PharmD, MPH, FAPhA, CDE, Vice President for Innovation at SinfoniaRx offers tips for pharmacists looking for inclusion in an ACO/PCMH model.
Advertisement
Sandra Leal, PharmD, MPH, FAPhA, CDE, Vice President for Innovation at SinfoniaRx offers tips for pharmacists looking for inclusion in an ACO/PCMH model.
Advertisement
Related to this article
Jai Radhakrishnan, MD, discusses why IgG4-related kidney disease is often missed and what MITIGATE subgroup data presented at ASN Kidney Week 2026 show
From AKI dosing to CKM therapeutic inertia, experts at ASN Kidney Week 2026 pointed to pharmacists as key to moving new kidney data into practice.
Kidney Week 2026 posters show low-density lipoprotein cholesterol (LDL-C) fell by half in patients receiving dialysis, and oral enlicitide needed no dose adjustment for renal impairment.
Walgreens adds virtual coverage navigation, Medicare GLP-1 Bridge support, and pharmacist follow-up calls as GLP-1 discontinuation remains high.
A helpful guide for pharmacists if teas, supplements, or cultural foods are part of a patient's regular routine.
Real-world data from ASN Kidney Week show GLP-1 RA users with CKD and obesity had lower rates of kidney failure, death, and heart failure exacerbation.
Hiddo J. L. Heerspink, PharmD, PhD, discusses SOLSTICE elecoglipron data, finerenone in FSGS, and glucagon’s kidney effects from ASN Kidney Week 2026.
Advertisement
Advertisement
Trending on Pharmacy Times
1
Cystatin C and the Future of Kidney Function Assessment
2
Walgreens Adds Pharmacist Outreach, Coverage Help for GLP-1s
3
GLP-1 RAs Tied to Lower Kidney Failure Risk in Patients With Obesity, CKD
4
The Growing Role the Specialty Pharmacy Team Plays in Helping Breast Cancer Patients Navigate Treatment
5